Overview of secondary liver cancer care pathways, key treatment steps, and the situations where dendritic cell treatment may be discussed as a selected option.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the ...

Liver cancer, primarily hepatocellular carcinoma, originates in the liver, with hepatitis B and C as major risk factors. Diagnosis involves physical exams, blood tests, imaging, and possibly biopsy to ...

At the 2025 European Society of Medical Oncology (ESMO) Congress 2025, held from17 to 21 October in Berlin, Germany, results from the Phase III IMbrave152/SKYSCRAPER-14 study were presented. The study ...

MASLD and Liver Cancer: What’s the Link? Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where too much fat builds up in your liver. Unlike fatty liver caused by heavy ...

Approximately 25% of patients with colorectal cancer present with metastatic disease to the liver at diagnosis, and about 50% develop liver metastases at some point during the course of the disease.